Published in AIDS Weekly, September 3rd, 2007
"The completion of this human trial is an important milestone in the development of BIT225", said Dr Michelle Miller, Managing Director, "We anticipate advancing the drug into Phase Ib/IIa clinical studies later this year." Protocols and regulatory applications for these new studies are being finalised.
The data from this Phase I clinical trial indicate BIT225 was well tolerated, with no dose limiting toxicities....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.